

AMENDMENTS TO THE CLAIMS

Please replace all prior versions, and listings, of claims in the application with the following list of claims:

1. (Original) A method of treating a mood disorder in an individual suffering from the mood disorder, comprising administering an effective amount of an antagonist of high affinity nicotinic acetylcholine receptors and at least one agent for treatment of the mood disorder to the individual.
2. (Original) The method of claim 1 wherein the mood disorder is major depressive disorder, dysthymic disorder, depressive disorder NOS, or bipolar disorder.
3. (Original) The method of claim 2 wherein the mood disorder is major depressive disorder and the antagonist of high affinity nicotinic acetylcholine receptors is mecamylamine or a salt thereof.
4. (Original) The method of claim 3, wherein the agent for treatment of the mood disorder is a tricyclic antidepressant, a monoamine oxidase inhibitor, a selective serotonin reuptake inhibitor or a selective norepinephrine reuptake inhibitor, a norepinephrine dopamine reuptake inhibitor.
5. (Original) The method of claim 1 wherein the agent for treatment of a mood disorder is a selective serotonin reuptake inhibitor.
6. (Original) The method of claim 4 wherein the selective serotonin reuptake inhibitor is citalopram, clovoxamine, escitalopram, femoxetine, flesinoxan, fluoxetine, fluvoxamine, paroxetine, setraline, trazodone, or zimeldine.

7. (Currently Amended) The method of claim 5 wherein the selective serotonin reuptake inhibitor ~~inhibitor~~ is citalopram, clovoxamine, escitalopram, femoxetine, flesinoxan, fluoxetine, fluvoxamine, paroxetine, setraline, trazodone, or zimeldine.

8. (Original) The method of claim 4 wherein the treatment comprises administering mecamylamine and a selective serotonin uptake inhibitor in a single formulation.

9-24. (Cancelled)

25. (New) A method for treating a mood disorder comprising administering exo-S-mecamylamine or a salt thereof, which is substantially free of exo-R-mecamylamine; and at least one additional agent.

26. (New) The method of claim 25, wherein the mood disorder is major depressive disorder, single episode major depressive disorder, recurrent episode major depressive disorder, hypomanic episode, manic episode, mixed episode, dysthymic disorder, depressive disorder NOS, depressive neurosis, depressive reaction, postpartum depression, premenstrual syndrome, neurotic depression, bipolar disorder, bipolar I disorder, bipolar II disorder, cyclothymic disorder, anxiety disorder, panic disorder, post-traumatic stress disorder, obsessive-compulsive disorder, social phobia, or depression.

27. (New) The method of claim 26, wherein the mood disorder is a refractory disorder.

28. (New) The method of claim 25, wherein the at least one agent is a tricyclic antidepressant, a monoamine oxidase inhibitor, a selective serotonin reuptake inhibitor, a selective norepinephrine reuptake inhibitor, a norepinephrine dopamine reuptake inhibitor, or other antidepressant.

29. (New) The method of claim 28, wherein:

(a) the tricyclic antidepressant is doxepin, amitriptyline, amoxapine, clomipramine, desipramine, imipramine, maprotiline, nortriptyline, protriptyline, trimipramine, or a salt thereof;

(b) the monoamine oxidase inhibitor is isocaboxazid, phenelzine, tranylcypromine, or a salt thereof;

(c) the selective serotonin reuptake inhibitor is citalopram, clovoxamine, escitalopram, femoxetine, flesinoxan, fluoxetine, fluvoxamine, paroxetine, sertraline, trazodone, zimeldine, or a salt thereof;

(d) the selective norepinephrine reuptake inhibitor is atomoxetine, venlafaxine, duloxetine, or a salt thereof; and

(e) the norepinephrine dopamine reuptake inhibitor is bupropion or a salt thereof.

30. (New) The method of claim 25, wherein the exo-S-mecamylamine is exo-S-mecamylamine hydrochloride.

31. (New) The method of claim 25, wherein the exo-S-mecamylamine or salt thereof is administered in a daily amount of from about 0.05 mg to about 15 mg; and the at least one additional agent is administered in a daily amount of from about 10 mg to about 80 mg.

32. (New) The method of claim 25, wherein the exo-S-mecamylamine or salt thereof is administered twice daily; and the at least one additional agent is administered once, twice, three, or four times daily.

33. (New) The method of claim 25, wherein the exo-S-mecamylamine or salt thereof and the at least one additional agent are administered together or individually.

34. (New) The method of claim 25, wherein the at least one additional agent is citalopram.

35. (New) The method of claim 34, wherein the mood disorder is refractory major depressive disorder.

36. (New) A method for adjunctively treating a mood disorder comprising administering exo-S-mecamylamine or a salt thereof, which is substantially free of exo-R-mecamylamine.